VCNX
- Vaccinex, Inc.
()
Overview
Company Summary
Vaccinex, Inc. (VCNX) is a biotechnology company that specializes in the development and commercialization of innovative therapeutic antibodies to treat various diseases, with a particular focus on cancer and neurodegenerative disorders. The company utilizes its proprietary technology platform known as ActivMab� Antibody Discovery Technology, which combines artificial intelligence (AI) and human antibody discovery to identify potential drug targets and create novel antibody candidates.
Vaccinex's primary focus is on antibody-based immunotherapies, which harness the body's immune system to fight diseases. By targeting specific proteins or antigens associated with diseases, these immunotherapies help activate the patient's immune response and enhance its ability to recognize and destroy diseased cells.
The company's lead product candidate, known as pepinemab (VX15), is being developed for the treatment of several diseases. In oncology, it is being evaluated for potential use in solid tumors with a focus on non-small cell lung cancer (NSCLC) and ovarian cancer. In neurology, Vaccinex is exploring the potential of pepinemab as a treatment for Huntington's disease, Alzheimer's disease, and other neurodegenerative disorders.
Vaccinex also collaborates with pharmaceutical companies, academic institutions, and research organizations to further expand its pipeline of therapeutic antibodies. These partnerships enable the company to leverage its discovery platform and advance multiple programs simultaneously.
In summary, Vaccinex, Inc. is a biotech company focused on developing and commercializing therapeutic antibodies for the treatment of cancer and neurodegenerative disorders, using its proprietary ActivMab� Antibody Discovery Technology. Through innovative research and collaborations, Vaccinex aims to provide potentially life-saving treatments for patients in need.